La Jolla Stock Dives on Lupus Drug News
From Dow Jones/Associated Press
Shares of La Jolla Pharmaceutical Co. plunged after the Food and Drug Administration required another study to approve the firm’s lupus drug.
The news sparked concern that the San Diego biotechnology company might not have enough money to get through another trial.
Shares of La Jolla fell $1.67 to $1.09 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
